Area:
Neuroscience Behavior Molecular Genetics Addiction
We are testing a new system for linking grants to scientists.
The funding information displayed below comes from the
NIH Research Portfolio Online Reporting Tools and the
NSF Award Database.
The grant data on this page is limited to grants awarded in the United States and is thus partial. It can nonetheless be used to understand how funding patterns influence mentorship networks and vice-versa, which has deep implications on how research is done.
You can help! If you notice any innacuracies, please
sign in and mark grants as correct or incorrect matches.
Sign in to see low-probability grants and correct any errors in linkage between grants and researchers.
High-probability grants
According to our matching algorithm, Scott D. Philibin is the likely recipient of the following grants.
Years |
Recipients |
Code |
Title / Keywords |
Matching score |
2003 — 2005 |
Philibin, Scott Dennis |
F31Activity Code Description: To provide predoctoral individuals with supervised research training in specified health and health-related areas leading toward the research degree (e.g., Ph.D.). |
Clozapine Drug Discrimination in C57bl/6j Mice @ Virginia Commonwealth University
DESCRIPTION (provided by applicant): Clozapine is the prototypical atypical antipsychotic drug and represents a tremendous improvement over conventional antipsychotics in terms of therapeutic efficacy and reduced side effect liability for the treatment of schizophrenia. Understanding the pharmacological properties that are important for clozapine's unique profile can help lead to the discovery of improved and safer antipsychotic drugs for the treatment of schizophrenia. One approach for investigating the molecular bases underlying the relationship of pharmacological agents and behavior has been the use of gene-targeted knockout or transgenic animals. This technique allows for the manipulation of receptors for which selective pharmacological ligands do not exist. One restriction of this approach is that most of the knockout mutations that have been developed are available only in mice - not rats. Therefore, it is necessary to have preclinical assays for mice in order to utilize these new and potentially powerful new techniques. The current proposal represents an important first step in this process. Two-lever drug discrimination is a valuable preclinical behavioral model that has been used to investigate the discriminative stimulus properties of clozapine in rats and has helped identify neurotransmitter receptor targets for putative atypical antipsychotics. Wild-type mice (C57BL/6J) will be trained to discriminate clozapine from vehicle and then a series of atypical and typical antipsychotic drugs will be tested to determine which drugs generalize to clozapine's discriminative cue. Establishing this procedure in wild-type mice will allow for the future use of knockout and transgenic mice and will expand the tools available to molecular geneticists and behavioral pharmacologists. This will help to increase our understanding of the perplexing pharmacology of schizophrenia.
|
0.93 |
2008 |
Philibin, Scott Dennis |
F32Activity Code Description: To provide postdoctoral research training to individuals to broaden their scientific background and extend their potential for research in specified health-related areas. |
Genetic Mouse Models of Ethanol Withdrawal: Role of Crf and Npy in Anxiety @ Oregon Health and Science University
[unreadable] DESCRIPTION (provided by applicant): Alcoholism is a prevalent disorder with a strong genetic component. Characterization of the behavioral genetic effects of ethanol will increase understanding and improve treatment for alcoholism. Alcoholism is associated with physical (e.g., convulsions) and psychological withdrawal symptoms (e.g., anxiety). The psychological symptoms are highly correlated with relapse in alcoholics. The goal of this application is to characterize anxiety related to genetic mouse models of ethanol withdrawal and neuropeptide Y (NPY) and corticotropin-releasing factor (CRF) peptide expression in the central (CeA), medial (MeA) and basolateral amygdala (BLA). The central hypothesis is that mice selectively bred for severe ethanol withdrawal convulsions will have increased ethanol withdrawal-induced anxiety associated with decreased NPY and increased CRF peptide levels in the CeA compared to mice bred for low withdrawal convulsion severity. The specific aims of this proposal are to (1) measure ethanol withdrawal-induced anxiety in the existing replicate lines of Withdrawal Seizure-Prone (WSP) and Withdrawal Seizure-Resistant (WSR) mice using several behavioral assays that measure contrasting and complementary anxiety-related behaviors, (2) measure [unreadable] NPY and CRF peptide expression in the CeA, MeA and BLA using immunohistochemical techniques to before ethanol exposure, immediately following chronic ethanol exposure and at peak withdrawal in chronic ethanol withdrawing WSP and WSR lines. Because WSP lines exhibit more basal as well as more ethanol withdrawal-induced anxiety behaviors than WSR lines, we predict that a genetic relationship between ethanol withdrawal and anxiety exists and that ethanol-withdrawal induced anxiety will be more severe in WSP versus WSR lines in additional models of ethanol withdrawal-induced behaviors related to anxiety. WSP lines are also predicted to have decreased NPY and increased CRF peptide basal levels in the CeA that are associated with anxiety and these effects will be potentiated during ethanol withdrawal. These studies will help elucidate the genetic basis of withdrawal and explore the potential roles of CRF and NPY in anxiety related to alcohol dependence that may lead to promising targets for drug treatments for alcoholism. [unreadable] [unreadable] [unreadable]
|
0.933 |